Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Model-based optimization approaches for precision medicine: A case study in presynaptic dopamine overactivity.

Hsu KC, Wang FS.

PLoS One. 2017 Jun 14;12(6):e0179575. doi: 10.1371/journal.pone.0179575. eCollection 2017.

2.

Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.

Eisenberg DP, Yankowitz L, Ianni AM, Rubinstein DY, Kohn PD, Hegarty CE, Gregory MD, Apud JA, Berman KF.

Neuropsychopharmacology. 2017 Oct;42(11):2232-2241. doi: 10.1038/npp.2017.67. Epub 2017 Apr 7.

PMID:
28387222
3.

Theranostic Biomarkers for Schizophrenia.

Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N.

Int J Mol Sci. 2017 Mar 30;18(4). pii: E733. doi: 10.3390/ijms18040733. Review.

4.

Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A.

Schizophr Bull. 2017 Jul 1;43(4):764-777. doi: 10.1093/schbul/sbw221.

PMID:
28187219
5.

Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.

Jauhar S, Veronese M, Rogdaki M, Bloomfield M, Natesan S, Turkheimer F, Kapur S, Howes OD.

Transl Psychiatry. 2017 Feb 7;7(2):e1027. doi: 10.1038/tp.2016.270.

6.

Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, Lee JS, Lee YS, Kwon JS.

Neuropsychopharmacology. 2017 Mar;42(4):941-950. doi: 10.1038/npp.2016.258. Epub 2016 Nov 18.

PMID:
27857125
7.

Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra.

Schoonover KE, McCollum LA, Roberts RC.

Neuropsychopharmacology. 2017 Jan;42(2):540-550. doi: 10.1038/npp.2016.164. Epub 2016 Aug 23.

PMID:
27550734
8.

Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors.

Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies DL.

J Neurochem. 2016 Oct;139(1):134-48. doi: 10.1111/jnc.13734. Epub 2016 Aug 15.

9.

Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A.

Biol Psychiatry. 2017 Jan 1;81(1):31-42. doi: 10.1016/j.biopsych.2016.03.2104. Epub 2016 Mar 31. Review.

PMID:
27206569
10.

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Arnsten AF, Girgis RR, Gray DL, Mailman RB.

Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Review.

PMID:
26946382
11.

Dopamine receptors and Parkinson's disease.

Hisahara S, Shimohama S.

Int J Med Chem. 2011;2011:403039. doi: 10.1155/2011/403039. Epub 2011 Jun 13. Review.

12.

Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia.

Mueller S, Wang D, Pan R, Holt DJ, Liu H.

JAMA Psychiatry. 2015 Jun;72(6):552-60. doi: 10.1001/jamapsychiatry.2014.3176.

13.

Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.

Wulff S, Pinborg LH, Svarer C, Jensen LT, Nielsen MØ, Allerup P, Bak N, Rasmussen H, Frandsen E, Rostrup E, Glenthøj BY.

Schizophr Bull. 2015 Sep;41(5):1143-52. doi: 10.1093/schbul/sbu220. Epub 2015 Feb 18.

14.

Glutamate and dopamine in schizophrenia: an update for the 21st century.

Howes O, McCutcheon R, Stone J.

J Psychopharmacol. 2015 Feb;29(2):97-115. doi: 10.1177/0269881114563634. Epub 2015 Jan 13. Review.

15.

Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.

Salavati B, Rajji TK, Price R, Sun Y, Graff-Guerrero A, Daskalakis ZJ.

Schizophr Bull. 2015 Jan;41(1):44-56. doi: 10.1093/schbul/sbu132. Epub 2014 Sep 22. Review.

16.

Glutamate-mediated excitotoxicity in schizophrenia: a review.

Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A.

Eur Neuropsychopharmacol. 2014 Oct;24(10):1591-605. doi: 10.1016/j.euroneuro.2014.07.015. Epub 2014 Aug 1. Review.

17.

Neuromelanin magnetic resonance imaging reveals increased dopaminergic neuron activity in the substantia nigra of patients with schizophrenia.

Watanabe Y, Tanaka H, Tsukabe A, Kunitomi Y, Nishizawa M, Hashimoto R, Yamamori H, Fujimoto M, Fukunaga M, Tomiyama N.

PLoS One. 2014 Aug 11;9(8):e104619. doi: 10.1371/journal.pone.0104619. eCollection 2014.

18.

The neurobiology and treatment of first-episode schizophrenia.

Kahn RS, Sommer IE.

Mol Psychiatry. 2015 Feb;20(1):84-97. doi: 10.1038/mp.2014.66. Epub 2014 Jul 22. Review.

19.

Ventral striatum gray matter density reduction in patients with schizophrenia and psychotic emotional dysregulation.

Stegmayer K, Horn H, Federspiel A, Razavi N, Bracht T, Laimböck K, Strik W, Dierks T, Wiest R, Müller TJ, Walther S.

Neuroimage Clin. 2013 Dec 27;4:232-9. doi: 10.1016/j.nicl.2013.12.007. eCollection 2014.

20.

Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study.

Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, Turkheimer F.

Brain. 2013 Nov;136(Pt 11):3242-51. doi: 10.1093/brain/awt264. Epub 2013 Oct 3.

Supplemental Content

Support Center